Containment Dermatology Protein 
XTalks
OCTOBER 24, 2024
While research is still ongoing, studies suggest that low-calorie diets, the Mediterranean diet and protein restriction may reduce inflammation. Nutrient-rich foods containing omega-3 fatty acids, prebiotics and curcumin could also help improve immune function and alleviate symptoms.
XTalks
AUGUST 7, 2023
Verrica, a company specializing in dermatology therapeutics, has designed Ycanth to be delivered through a single-use applicator. It then activates enzymes known as neutral serine proteases, which are responsible for protein degradation. ’s berdazimer gel, containing 10.3 Another noteworthy contender is Novan Inc.’s
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
NOVEMBER 4, 2020
TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.
The Pharma Data
JANUARY 13, 2021
Brilacidin is a first-in-class Host Defense Protein (HDP) mimetic with antiviral, anti-inflammatory and antibacterial properties. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of Brilacidin as a potential treatment for COVID-19.
The Pharma Data
JULY 8, 2021
Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation. 1) as determined by an FDA-approved test.
The Pharma Data
AUGUST 19, 2020
Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Food and Drug Administration. An estimated 2.5
Bioengineer
JULY 20, 2021
Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Octagam® 10% does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or renal failure, administer Octagam® 10% at the minimum infusion rate practicable. About the Octapharma Group.
Expert insights. Personalized for you.
105 
Let's personalize your content